FDA Approves DILTIAZEM HYDROCHLORIDE — ScieGen Pharmaceuticals, Inc.
ScieGen Pharmaceuticals has secured FDA approval for its Abbreviated New Drug Application (ANDA) 216327, granting it market rights to the generic version of Diltiazem Hydrochloride, an oral formulation. This regulatory green light enables ScieGen to capitalize on the established generic market for this cardiovascular therapeutic.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day